Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace
Full Data Set from Phase I First-in-Human Helped Establish Doses for Phase IIA Multiple Ascending Dose StudyATLANTA (BUSINESS WIRE) $ACAD #ACImmune Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodeg.